NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Chou R, McDonagh MS, Nakamoto E, et al. Analgesics for Osteoarthritis: An Update of the 2006 Comparative Effectiveness Review [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2011 Oct. (Comparative Effectiveness Reviews, No. 38.)

Cover of Analgesics for Osteoarthritis

Analgesics for Osteoarthritis: An Update of the 2006 Comparative Effectiveness Review [Internet].

Show details

Appendix DInclusion and Exclusion Criteria

Abstract-Level Eligibility Criteria

Study CharacteristicInclusion/Exclusion
PopulationInclude: all ages >18; patients with osteoarthritis (for studies reporting benefits or harms); patients with rheumatoid arthritis, Alzheimer’s or enrolled in cancer prevention trials (for studies reporting harms)
Exclude: Juvenile populations; Post-surgical pain patients
InterventionsInclude: acetaminophen, aspirin, celecoxib, chondroitin, diclofenac, diflunisal, etodolac, fenoprofen, flurbiprofen, glucosamine, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamate sodium, mefenamic acid, meloxicam, nabumetone, naproxen, oxaprozin, piroxicam, salsalate, sulindac, tolmetin
Exclude: all other medications, including COX-2 and other drugs included in previous report but no longer FDA approved for use in the United States
ComparatorsInclude: any above medication, placebo
Exclude: drugs not included in this review
OutcomesInclude: Improvements in osteoarthritis symptoms; Adverse events: any cardiovascular, gastrointestinal, renal toxicity, hepatic toxicity; quality of life; sudden death
Timing/DurationInclude any study duration (no minimum exposure)
SettingInclude primary care or specialty setting
Study DesignInclude: RCT, cohort, case control, systematic review, meta-analysis

Full-Text Eligibility Criteria

Study CharacteristicInclusion/Exclusion
PopulationInclude: all ages >18; patients with osteoarthritis (for studies reporting benefits or harms); patients with rheumatoid arthritis, Alzheimer’s or enrolled in cancer prevention trials (for studies reporting harms)
Exclude: Juvenile populations; post-surgical pain patients
InterventionsInclude: acetaminophen, aspirin, celecoxib, chondroitin, diclofenac, diflunisal, etodolac, fenoprofen, flurbiprofen, glucosamine, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamate sodium, mefenamic acid, meloxicam, nabumetone, naproxen, oxaprozin, piroxicam, salsalate, sulindac, tolmetin
Exclude: all other medications, including COX-2 and other drugs included in previous report but no longer FDA approved for use in the United States; combination therapies of multiple NSAIDs
ComparatorsInclude: any above medication, placebo
Exclude: drugs not included in this review
OutcomesInclude: Improvements in osteoarthritis symptoms; Adverse events: any cardiovascular, gastrointestinal, renal toxicity, hepatic toxicity; quality of life; sudden death
Timing/DurationInclude any study duration (no minimum exposure)
SettingInclude primary care or specialty setting
Study DesignInclude: RCT, cohort, case control, systematic review, meta-analysis
Exclude: cohort or case control study with <1000 patients, dose-ranging study, pharmacokinetics, single-dose study, drug interaction, case report, nonsystematic review

Views

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...